Repligen (NASDAQ:RGEN) Research Coverage Started at Evercore ISI

Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN) in a research report sent to investors on Tuesday morning, Marketbeat reports. The firm issued an in-line rating and a $155.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Royal Bank of Canada increased their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Finally, TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen currently has a consensus rating of “Hold” and a consensus target price of $178.64.

Repligen Trading Down 3.8 %

Shares of RGEN stock opened at $139.34 on Tuesday. Repligen has a 52-week low of $113.50 and a 52-week high of $200.23. The stock has a market cap of $7.81 billion, a price-to-earnings ratio of -273.22, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a fifty day moving average of $156.47 and a 200-day moving average of $148.40.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. On average, equities research analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of RGEN. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the 4th quarter valued at about $29,000. Raiffeisen Bank International AG acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $29,000. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $37,000. Finally, Quarry LP raised its position in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.